Hologic breast surgery device affirmed by study
Photo | Courtesy | Hologic
Hologic's BioZorb device
A new study has demonstrated the safety and clinical effectiveness of a device Hologic is developing to aid with breast surgery.
The study published in the Annals of Surgical Oncology, which Hologic announced late Tuesday, affirms the potential of the Marlborough medical device company's product, BioZorb. It is the first large, multi-center study to report 24-month outcomes after using BioZorb as part of breast-conserving surgery, Hologic said.
BioZorb is implanted to aid with precision during breast surgery and radiation therapy, and is designed to absorb into the body over a year or more.
In the study, patients and surgeons said BioZorb gave a significant cosmetic benefit, with 90% or more of patients reporting good or excellent long-term outcomes with low adverse effects.
WBJ Web Partners
Most Recent
Most Recent
0 Comments